Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions

Saori Fujita-Sato1,2, Jacqueline Galeas1, Morgan Truitt1, Cameron Pitt1, Anatoly Urisman3, Sourav Bandyopadhyay1, Davide Ruggero1, and Frank McCormick1

Abstract

Oncogenic K-Ras mutation occurs frequently in several types of cancers, including pancreatic and lung cancers. Tumors with K-Ras mutation are resistant to chemotherapeutic drugs as well as molecular targeting agents. Although numerous approaches are ongoing to find effective ways to treat these tumors, there are still no effective therapies for K-Ras mutant cancer patients. Here we report that K-Ras mutant cancers are more dependent on K-Ras in anchorage-independent culture conditions than in monolayer culture conditions. In seeking to determine mechanisms that contribute to the K-Ras dependency in anchorage-independent culture conditions, we discovered the involvement of Met in K-Ras–dependent, anchorage-independent cell growth. The Met signaling pathway is enhanced and plays an indispensable role in anchorage-independent growth even in cells in which Met is not amplified. Indeed, Met expression is elevated under anchorage-independent growth conditions and is regulated by K-Ras in a MAPK/ERK kinase (MEK)-dependent manner. Remarkably, in spite of a global downregulation of mRNA translation during anchorage-independent growth, we find that Met mRNA translation is specifically enhanced under these conditions. Importantly, ectopic expression of an active Met mutant rescues K-Ras ablation-derived growth suppression, indicating that K-Ras–mediated Met expression drives "K-Ras addiction" in anchorage-independent conditions. Our results indicate that enhanced Met expression and signaling is essential for anchorage-independent growth of K-Ras mutant cancer cells and suggests that pharmacological inhibitors of Met could be effective for K-Ras mutant tumor patients.

Introduction

K-Ras mutations are frequently found in pancreatic, lung, and colorectal tumors (1–3). These mutations are predominantly somatic missense mutations at position 12, 13, or 61 that impair the GTPase activity of K-Ras and result in constitutive activation of downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Even after three decades of research, many questions remain as to how mutant K-Ras contributes to tumor initiation and progression. There are currently no effective treatments for cancers with mutant K-Ras. Patients with K-Ras mutant tumors are associated with resistance to chemotherapy, radiation, and epidermal growth factor receptor (EGFR) targeted therapies (4–8), and tend to have poor overall survival (9–12). Numerous research efforts to develop therapeutic agents to directly inhibit oncogenic Ras have thus far been unsuccessful (13), and the focus has therefore been on targeting druggable molecules in the pathways downstream of Ras. In this regard, combination therapies with mitogen-activated protein kinase kinase (MEK) and PI3K pathway inhibitors have been shown to be effective in mouse tumor models harboring mutant K-Ras (14–16), and some combinations of these inhibitors are already in clinical trials.

The dependency on K-Ras for growth in monolayer culture conditions varies widely between different K-Ras mutant cell lines as evaluated by the growth suppression rate after K-Ras depletion with RNA interference (RNAi). Although K-Ras dependency has been shown to correlate with elevated expression of K-Ras and E-cadherin, the contribution of two major K-Ras downstream signaling molecules, Akt and MAPK, to K-Ras dependency is unclear (17, 18). Compared with in vitro culture conditions, however, K-Ras mutant cells are known to be more broadly dependent on K-Ras in vivo (19–21). Cells change the strength of many signaling pathways in response to different culture conditions, suggesting that the importance of specific signaling pathways for survival or proliferation would change in response to distinct environmental changes (22–24). Recent data have shown that pancreatic cancer cells cultured in anchorage-independent conditions express higher levels of stem cell markers and show higher tumorigenicity in vivo than cells in adherent conditions (25), suggesting that anchorage-independent culture conditions are more reflective of in vivo tumor conditions.

1Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. 2Oncology Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. 3Department of Pathology, University of California San Francisco, San Francisco, California.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Frank McCormick, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1450 3rd Street HD371, San Francisco, CA 94143. Phone: 415-502-1710; Fax: 415-502-1712; E-mail: mccormic@cc.ucsf.edu

doi: 10.1158/0008-5472.CAN-14-1623
©2015 American Association for Cancer Research.
growth. Thus, the use of an in vitro anchorage-independent culture model may identify more relevant in vivo signaling pathways downstream of K-Ras.

Hepatocyte growth factor (HGF) and its receptor Met regulate various signaling pathways that contribute to physiological processes such as embryonic development, organ regeneration, and wound healing (26). Dereglution of this signaling pathway frequently occurs in many different types of cancers via Met mutation or overexpression in the tumor, or HGF overexpression in the surrounding stroma, resulting in the promotion of tumor growth, invasion, and metastasis (27, 28). Moreover, increased HGF/Met signaling is known to cause resistance to many small molecule inhibitors, such as the BRAF inhibitor vemurafenib (PLX4032) and several receptor tyrosine kinase (RTK) inhibitors, including the EGFR inhibitors gefitinib and erlotinib, the Her2/EGFR inhibitor lapatinib, and the anaplastic lymphoma kinase inhibitor TAE684 (29). Currently, several small molecule compounds and antibodies targeting HGF/Met are under clinical development, including the Met kinase inhibitor cabozantinib, which was recently approved by the FDA for the treatment of medullary thyroid cancer.

In this report, we compared K-Ras mutant tumor cells for their dependency on K-Ras during growth in monolayer culture conditions and in anchorage-independent culture conditions and found that cells were more dependent on K-Ras in anchorage-independent conditions. Analysis comparing the activation state and dependencies of various signaling pathways between these culture conditions revealed that Met plays a critical role in proliferation and drives, at least in part, the enhanced K-Ras dependency observed specifically in anchorage-independent culture conditions. Further analysis revealed that K-Ras/MEK signaling regulates Met mRNA expression, whereas anchorage-independent culture conditions promotes increased translation of Met mRNA. Thus, our results uncover novel modes of regulation underlying Met expression, which is critical for anchorage-independent growth of K-Ras mutant tumor cells. These findings suggest that pharmacological inhibitors of Met could have significant therapeutic potential for the treatment of K-Ras mutant cancers.

Materials and Methods

Reagents and cell culture

PHA-665752, XI-184, MK2206, GSK-1120212, and BKM120 were from Selleckchem. 4EGI-1 was from Calbiochem. Human and mouse HGF, human basic FGF, and human EGF were from Propeptech and Sigma-Aldrich. Antibodies were obtained from: Met, pMet(Y1003, Y1234/Y1349), pAKT(S473), pERK(Y202/Y204), ERK, pMEK, MEK, EGFR, Cyclin D1, eIF4E, and eIF4G antibodies from Cell Signaling Technology; actin and mouse HGF, human basic FGF, and human EGF were from Selleckchem. 4EGI-1 was from Calbiochem. Human cancer cell line HCT116, and human lung cancer cell line A549 were maintained in RPMI (Life Technologies) supplemented with 10% FBS and 500 μg/mL penicillin and 500 μg/mL streptomycin. To generate 'Rasless' MEFs, 4-hydroxytamoxifen (4-OHT; Sigma) was used at a final concentration of 600 nmol/L for 12 days.

siRNA transfection

Cells were transfected with the appropriate siRNAs (Thermo Scientific) at a final concentration of 1 to 10 nmol/L using Lipofectamine RNAiMAX reagent (Life Technologies) according to the manufacturer’s instructions.

Vector construction and lentivirus production

Full-length wild-type human Met in pDONR223 (Addgene) and all Ras cDNAs were cloned into pLenti CMV/TO Puro or pLenti CMV Blast (Addgene) by LR reaction (Life Technologies). Met or Ras active mutants were generated by PCR amplification. Lentivirus was produced by UCSF ViraCore or by cotransfection of the corresponding lentiviral vector with a packaging system into 293FT cells using the standard protocol for Lipofectamine 2000 (Invitrogen). Cells were infected with lentiviruses in the presence of polybrene (Millipore) at a final concentration of 8 μg/mL.

Data analysis of Met expression and K-Ras mutation status

Met mRNA expression levels in 807 cell lines with or without K-Ras mutations were analyzed using the cell line encyclopedia. Comparison of normalized Met mRNA expression levels in K-Ras mutant versus wild-type samples in the pancreatic TCGA project. Data were obtained from http://www.cbioportal.org.

Growth assay

Cells were seeded at 1.25 to 2.5 x 10^5 cells/well (monolayer) or 2.5 to 5 x 10^3 cells/well (anchorage independent) in 96-well plates (monolayer; Becton Dickinson) or 96-well Ultra Low Attachment plates (anchorage independent; Corning). After incubation for indicated time periods, CellTiter Glo (Promega) was added in each well and the mixture was transferred to 96-well white plates (Corning). Luminescence was analyzed by GLOMAX (Promega).

Western blot analysis

Cells were lysed in 1% Triton lysis buffer [20 mmol/L Tris pH 7.5, 135 mmol/L NaCl, 1% Triton X-100, 10% glycerol, 1 mmol/L EDTA] supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails (Sigma) and cleared by centrifugation (13,000 rpm, 10 minutes). Protein concentration was measured using a Bio-Rad modified Bradford Protein Assay (Bio-Rad). Lysates were boiled in 1 x SDS sample buffer. Equivalent protein quantities were run on SDS-PAGE (NuPAGE; Invitrogen), transferred to nitrocellulose (iBlot; Invitrogen), and probed with the indicated primary antibodies. Subsequently, primary antibodies were detected with secondary antibodies conjugated to horseradish peroxidase (GE Healthcare). Blots were visualized with an enhanced...
chemiluminescence system, according to the manufacturer’s instructions (GE Healthcare).

Real-time PCR
RNA was extracted with RNeasy Mini Kit using DNase I (Qiagen), and cDNA was synthesized with high-capacity cDNA reverse transcription kits (Applied Biosystems). SYBR Green PCR Master Mix with Mn300p qPCR system (Agilent Technologies) was used for analysis of cDNA by real-time PCR. The expression of each gene was normalized to the expression of β-actin by the standard curve method. The primer sets were as follows: Met ACCGTCAACAGAGGGACCCT and GCACTGAACTTCGGACTGTATG; β-actin ACTCTGGGACCATGGGAAAAAT and TGGAAACCTCACTCACG; eIF4G3 CCTAGAGCTACCATCCCGAAC and GGGCCAGGGCAAAACGCTCAGAAATG and TCCTGAAGATTGCATCA-TGTCG; eIF4G1 CCGGAAAAAGAACCACCGAAG and TCCCTCCTGATGCTTCATCGC; eIF4G2 AGGGCAAACCGTCAAGAAATG and TCCCTGAAGATTTGACATC-TGTCG; eIF4G3 CCTAGAGCTACCATCCCGAAC and GGGCCACTATGACGTCTACGTG.

Polysome fractionation and analysis of polysomal-associated mRNA
Monolayer and anchorage-independent cell cultures were harvested 72 hours after plating and incubated with 100 μg/mL cyclohexamide (Sigma) in PBS for 5 hours on ice. Cells were pelleted and lysed in 10 mmol/L Tris-HCl pH 8, 140 mmol/L NaCl, 1.5 mmol/L MgCl₂, 0.25% NP-40, 0.1% Triton-X 100, 50 mmol/L dithiothreitol, 150 μg/mL cyclohexamide, and 640 U/mL RNasin for 30 minutes. Lysates were cleared by centrifugation for 5 minutes at 9,300 × g and loaded onto a 10% to 50% sucrose gradient. Loaded sucrose gradients were spun at 37,000 rpm for 2.5 hours at 4°C in a Beckman L-8-70M ultracentrifuge. Sucrose gradients were then fractionated on an ISCO gradient fractionation system to assess polyosomal profiles and collect polysomal mRNA. RNA was isolated from gradient fractions using TRizol Reagent (Invitrogen) and Pure Link RNA mini kits (Invitrogen) according to the manufacturer’s protocol. Purified RNA was reverse transcribed to cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA samples were diluted 1:4 and 1 μL of template was used in a SYBR Green qPCR assay (Bio-Rad) run on a MyiQ2 Real-Time PCR Detection System (Bio-Rad) to determine Met mRNA expression relative to β-actin. The primer sets used were as follows: Met ACCGTCAACAGAGGGACCCT and GCACTGAACTTCGGACTGTATG; β-actin GCAAAAGCCTG-TAGCCCAAC and AGTACTTGGCCTCAGAGGA.

Statistical analysis
All analyses for statistically significant differences were performed with the two-tailed unpaired Student t test. P-values less than 0.05 were considered significant. All error bars shown in the figures in this article are SD.

Results
K-Ras mutant cell lines are more dependent on K-Ras in anchorage independent than in monolayer culture conditions
To understand the alterations of K-Ras dependencies in response to environmental changes in K-Ras mutant cancer cells, we first introduced a siRNA targeting K-Ras to cells and cultured them in monolayer and anchorage-independent culture conditions. Consistent with previous reports (17, 18), in monolayer conditions, the growth of A549 and Panc1 cells was relatively resistant to K-Ras depletion, whereas Capan1 cell growth was decreased markedly upon K-Ras knockdown, reflecting the different degrees of K-Ras requirements among these cell lines in this culture condition. Interestingly, K-Ras depletion resulted in striking growth suppression in all three cell lines in anchorage-independent culture conditions (Fig. 1A and B). To exclude the possibility of off-target effects of the siRNA, three additional siRNAs targeting different sequences of K-Ras were also used for proliferation assays and gave similar results (Supplementary Fig. S1). These results suggest that in K-Ras mutant cancer cells, where K-Ras may be dispensable for cell proliferation in monolayer conditions, K-Ras plays an indispensable role in cell proliferation in anchorage-independent conditions.

Met signaling is upregulated in anchorage-independent culture conditions
To identify differences in the signaling profiles between monolayer and anchorage-independent culture conditions, the expression and phosphorylation of several different signaling proteins were analyzed. Strikingly, compared with monolayer conditions, Met protein expression and phosphorylation was found to be upregulated in anchorage-independent conditions in several pancreatic, colorectal, and lung cancer cell lines harboring mutant K-Ras (Fig. 2A). In addition, Met phosphorylation could be inhibited by addition of the Met-specific inhibitor, PHA-665752, in line with the activation of Met signaling in anchorage-independent culture conditions. Importantly, all of these cell lines were found to be more dependent on K-Ras for growth in anchorage-independent culture conditions than monolayer conditions (Supplementary Fig. S2).

To exclude the possibility that the increase in Met in anchorage-independent conditions is caused by the selection of cells with higher Met expression, we cultured cells in anchorage independent conditions for 3 days, and then switched them to monolayer conditions and incubated for an additional 2 days. Met protein levels significantly increased after 3 days of anchorage-independent culture, and decreased after an additional 2 days in monolayer cultures (Fig. 2B). Notably, EGFR expression was not altered by the change in culture conditions for either cell line. These results suggest that the culture condition itself alters Met protein expression levels.

Increased contribution of HGF/Met signaling to cell proliferation in anchorage-independent culture conditions
Given the increase in protein and phosphorylation levels of Met in the anchorage-independent conditions, we hypothesized that Met signaling may play a more significant role for cell proliferation in anchorage-independent culture conditions than in monolayer culture conditions (Fig. 1A). To address this, we introduced two siRNAs targeting different Met sequences (Met si-1 and Met si-2) and compared their effects on cell proliferation in monolayer and anchorage-independent culture conditions (Fig. 3A and B). Met knockdown efficiently suppressed Met expression in Capan1 and A549 cells (Fig. 3C). Growth of both Capan1 and A549 cells was more sensitive to Met ablation under anchorage-independent culture conditions than monolayer culture conditions, although the growth inhibitory effect was weaker than that seen with K-Ras ablation (Fig. 3A and B). In monolayer conditions, A549 cells contain lower levels of Met protein than
Met amplified cells, and are resistant to Met inhibitors (30). However, we found that anchorage-independent culture of A549 cells induces Met expression and renders them sensitive to Met depletion. Similar results were observed with CFPAC1 and ASPC1 cells (data not shown).

We next sought to determine whether pharmacological inhibition of Met would, similar to Met knockdown, affect cell proliferation more significantly under anchorage-independent conditions than monolayer conditions. Capan1 cells were incubated with different concentrations of the Met-specific inhibitor PHA-665752 or XL-184 (cabozantinib), a dual VEGFR2 and Met inhibitor that has recently been approved by the FDA. Both compounds inhibited Met phosphorylation (Fig. 3D) and, consistent with a previous report (30), increased Met protein expression levels in cells upon prolonged exposure. Strikingly, both compounds inhibited cell growth in a dose-dependent manner only when cells were cultured in anchorage-independent conditions (Fig. 3E).

Figure 1.
Effect of K-Ras knockdown on proliferation of K-Ras mutant cell lines in monolayer and anchorage-independent culture conditions. A, cell proliferation after siRNA-mediated K-Ras ablation in K-Ras-mutated A549, Panc1, and Capan1 cells. One day after transfection of control or K-Ras siRNA, cells were seeded on normal cell culture plates (monolayer) or ultra-low attachment plates (anchorage independent). Relative viable cell numbers were estimated by quantitating ATP present in each well after the indicated time points. Data are shown as the mean ± SD of quadruplicate samples. B, the same cells as in A were collected after 96 hours of siRNA transfection. Cell lysates were immunoblotted with the indicated antibodies. Repeated experiments gave similar results. C, control siRNA; K, K-Ras siRNA.
In tumors, Met signaling can be enhanced by increased Met expression, activating Met mutations or HGF overexpression. The main source of HGF is not thought to be the cancer cells themselves but instead the surrounding stroma (27). In line with this, HGF mRNA or HGF protein expression was below detection levels in Capan1 and Suit2 cells (data not shown). Therefore, in order to further explore the significance of Met signaling pathways, we next stimulated cells with recombinant human HGF in monolayer and anchorage-independent culture conditions. Stimulation of the cells with human HGF resulted in the phosphorylation of Met in both conditions (Fig. 3F). However, the degree of HGF-induced Met phosphorylation was significantly higher in anchorage-independent culture conditions than in monolayer culture conditions (Fig. 3F). Consistent with these results, HGF promoted proliferation of cells cultured in anchorage-independent culture conditions significantly more than in monolayer conditions (Fig. 3G and Supplementary Fig. S3A) and Met kinase inhibitor treatment suppressed this effect (Supplementary Fig. S3A), indicating that the HGF/Met signaling pathway supports anchorage-independent growth of K-Ras mutant cancer cells. In contrast, EGF stimulation slightly enhanced cell growth to similar degrees in monolayer and anchorage-independent culture conditions (Supplementary Fig. S3B and S3C), consistent with the observation that EGFR levels were identical between the two conditions (Fig. 2B). Together, these observations strongly suggest that HGF/Met signaling contributes to K-Ras–dependent cell proliferation specifically in anchorage-independent culture conditions.

K-Ras/MEK signaling regulates Met expression

Our results demonstrate that both K-Ras and Met play an essential role in anchorage-independent cell growth of K-Ras mutant cancer cells. Although K-Ras is a known effector of Met, other mechanisms linking K-Ras and Met signaling may play a role in anchorage-independent cell growth. To examine the relationship between K-Ras and Met, we knocked down either K-Ras or Met and examined their effects on the expression of other. As shown in Fig. 4A, K-Ras ablation decreased the phosphorylation levels of Met in both conditions (Fig. 3F). However, the degree of HGF-induced Met phosphorylation was significantly higher in anchorage independent culture conditions than in monolayer culture conditions (Fig. 3F). Consistent with these results, HGF promoted proliferation of cells cultured in anchorage-independent culture conditions significantly more than in monolayer conditions (Fig. 3G and Supplementary Fig. S3A) and Met kinase inhibitor treatment suppressed this effect (Supplementary Fig. S3A), indicating that the HGF/Met signaling pathway supports anchorage-independent growth of K-Ras mutant cancer cells. In contrast, EGF stimulation slightly enhanced cell growth to similar degrees in monolayer and anchorage-independent culture conditions (Supplementary Fig. S3B and S3C), consistent with the observation that EGFR levels were identical between the two conditions (Fig. 2B). Together, these observations strongly suggest that HGF/Met signaling contributes to K-Ras–dependent cell proliferation specifically in anchorage-independent culture conditions.
Figure 3.
Involvement of Met-driven signaling pathways in the growth of cells in anchorage-independent culture conditions. A and B, Capan1 (A) or A549 (B) cells were transfected with control siRNA, K-Ras siRNA, or Met siRNAs. Twenty-four hours after transfection, cells were harvested and seeded onto normal cell culture plates (monolayer) or ultra-low attachment plates (anchorage independent), and relative cell growth was analyzed 3 days (Capan1) or 4 days (A549) after cell seeding. Data were normalized with each control siRNA-transfected sample and are shown as the mean ± SD of quadruplicate samples. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.0001. C, the effects of each siRNA were confirmed by Western blot analysis 3 days after siRNA transfection. D, Capan1 cells were incubated with medium containing vehicle (DMSO), 500 nmol/L PHA-665752 (PHA), or 500 nmol/L XL184 (XL) in monolayer culture conditions for 2 days. Cell lysates were immunoblotted with the indicated antibodies. Repeated experiments gave similar results. (Continued on the following page.)
K-Ras activation status, showing that, in general, cell lines with mutant K-Ras express higher levels of Met mRNA than cells with wild-type K-Ras (Fig. 4C). Moreover, analysis of human patient samples demonstrated that pancreatic cancers with mutant K-Ras also express higher levels of Met mRNA than those with wild-type K-Ras (Fig. 4D).

To further investigate the role of K-Ras on Met expression, we used “Rasless” MEIs completely devoid of all three Ras isoforms (H-, N-, and K-Ras) and re-introduced exogenous wild-type or mutant (G12D or G12V) forms of K-Ras. Ectopic expression of either wild-type or mutant K-Ras in the Rasless cells elevated Met protein levels (Fig. 4E). Interestingly, MEIs ectopically expressing K-Ras, but not Rasless MEIs, enhanced Met phosphorylation levels drastically after HGF stimulation (Fig. 4E). Together, these findings strongly suggest that K-Ras–driven signaling is essential for Met expression and function.

To identify intermediaries in the K-Ras/Met axis, cells were incubated with small molecule kinase inhibitors targeting Akt (MK2206), MEK1/2 (GSK 1120212), and/or PI3K (BKM120). Only inhibition of MEK1/2 significantly decreased Met protein levels, indicating that K-Ras–driven MEK signaling is responsible for Met expression (Fig. 4F). In addition, qPCR analysis revealed that K-Ras knockdown or MEK inhibitor treatment decreased Met mRNA expression (Fig. 4G). Moreover, cells were more sensitive to MEK1/2 inhibition in anchorage-independent culture conditions than in monolayer conditions, consistent with an enhanced requirement for Met during anchorage-independent growth (Supplementary Fig. S4). Collectively, these results demonstrate that the K-Ras/MEK signaling pathway positively regulates Met mRNA levels.

Ectopic expression of active Met rescues K-Ras ablation-induced growth suppression

Our observations that cells with mutant K-Ras required both K-Ras and Met for proliferation in anchorage-independent conditions and that K-Ras/MEK signaling positively regulated Met expression prompted us to examine the biological significance of crosstalk between these two pathways. To directly evaluate the role of Met in K-Ras mutant cancer cells, a lentiviral system was used to express a constitutively active M1268T Met mutant. The M1268T mutation in Met was originally identified in papillary renal carcinomas and is reported to cause enhanced Met phosphorylation and activation (28, 31). Met(M1268T) expression increased basal phosphorylation levels of Met and partially restored the phosphorylation levels of Met and Akt after K-Ras knockdown in Capan1 cells (Fig. 5A). Importantly, expression of Met (M1268T) promoted the growth of K-Ras–depleted cells only in anchorage-independent culture conditions (Fig. 5B). Similar results were obtained using A549 cells (Supplementary Fig. S5). These data suggest that K-Ras–mediated Met expression contributes to K-Ras-mediated cell proliferation in anchorage-independent culture conditions.

Met translation is specifically enhanced in anchorage-independent culture conditions

Although K-Ras and Met contributed to cell proliferation more in anchorage-independent culture conditions than in monolayer culture conditions, knockdown of K-Ras decreased Met protein levels both in anchorage-independent and monolayer culture conditions (Fig. 4A), indicating that K-Ras/MEK-mediated regulation of Met mRNA expression does not change between these two conditions. To understand the mechanism by which Met protein levels increase specifically in anchorage-independent conditions, we first tested whether the half-life of Met protein is altered between the two culture conditions. Capan1 and Suit2 cells were cultured in anchorage-independent or monolayer conditions for 3 days, and then a new protein synthesis was inhibited with cycloheximide (CHX). Immunoblot analysis at different time points after CHX treatment showed similar profiles for Met half-life in anchorage-independent and monolayer culture conditions, indicating that anchorage-independent culture does not alter the turnover of Met protein (Supplementary Fig. S6A). Furthermore, qPCR analysis showed no difference in Met mRNA levels between cells cultured in anchorage-independent or monolayer conditions (Fig. 4G).

Previous reports indicated that Met expression could be positively regulated by cap-dependent translation through increased expression of the cap-binding protein eIF4E (32). Therefore, in order to test the possibility that cap-dependent Met translation is enhanced during anchorage-independent culture, we assessed the effect of anchorage-independent conditions on both global mRNA translation as well as Met-specific mRNA translation. Interestingly, analysis of polysome profiles uncovered a profound decrease of global translation under anchorage-independent growth conditions, where there was a relative loss of actively translating polyribosomes and accumulation of monosomes (Fig. 6A). Remarkably, however, we found that Met mRNA translation was instead enhanced under anchorage-independent growth conditions, as revealed by a shift in Met mRNA association towards more actively translating polysomal fractions (Fig. 6B and Supplementary Fig. S6B). As enhanced Met translation has previously been attributed to increased eIF4E expression, we next evaluated mRNA expression levels of the eIF4F components, elf4E, elf4G1, elf4G3, and elf4G2. Despite enhanced Met translation in anchorage-independent growth conditions, we found that elf4E mRNA levels were unaffected by culture conditions, although there was an increase in elf4G3 expression (Supplementary Fig. S6C). Consistent with previous work (32), we found that inhibition of elf4E-dependent translation with the small molecule 4EGI-1 decreased Met protein levels. However, the decrease was more significant in cells cultured in monolayer conditions, indicating that Met expression is less dependent on elf4E when cells are cultured in anchorage-independent conditions (Fig. 6C). These results suggest that Met translation is specifically increased in cells cultured in anchorage-independent conditions, perhaps in part through cap-independent mechanisms.

(Continued)
Figure 4.
K-Ras regulates Met expression via MEK. A, Suit2 and Capan1 cells were transfected with either control siRNA (C) or K-Ras siRNA (K). Twenty-four hours after transfection, cells were harvested and seeded on normal cell culture plates (Mo, monolayer) or ultra-low attachment plates (Al, anchorage independent). Seventy-two hours after seeding, cells were harvested and immunoblotted with the indicated antibodies. B, twenty-four hours after transfection of control siRNA (C) or K-Ras siRNA (K), Suit2, Capan1, and BxPC3 cells were cultured in monolayer culture conditions for additional 72 hours. Repeated experiments gave similar results. C, each cell line was grouped as K-Ras wild-type (WT) or K-Ras mutant (Mutant) and their relative Met mRNA levels plotted. (Continued on the following page.)
to sustain higher Met protein levels necessary for anchorage-independent growth.

Together, our data support a model in which mutant K-Ras contributes to Met expression, which is increased in anchorage-independent culture conditions via increased translation, causing increased Met-driven proliferation and a stronger dependence on K-Ras.

Discussion

The ability of cells to grow in anchorage-independent and sphere forming culture conditions is known to reflect some characteristics of tumor cells, including self-renewal ability (25, 33). Thus, in many cases, anchorage-independent cell culture may be a better model for cancer studies. Here we have demonstrated that cancer cells with active K-Ras mutations are more dependent on K-Ras–driven signaling in anchorage-independent culture than in monolayer culture (Fig. 1A). In investigating the mechanisms for this distinction in K-Ras dependency, we discovered that Met plays a pivotal role in anchorage-independent conditions, potentially acting upstream of the Akt pathway (Fig. 5A). Met translation and activation were increased when cells were cultured in anchorage-independent conditions (Fig. 2), leading to a stronger dependence of cells for Met, as seen by attenuated cell proliferation upon Met knockdown or Met inhibitor treatment (Fig. 3). Furthermore, we found Met expression levels to be dependent on K-Ras/MEK signaling (Fig. 4).

Although we could not detect HGF expression in our cancer cells lines (data not shown), we observed an increase in phospho-Met levels in anchorage-independent culture conditions (Fig. 2).

Recent work has demonstrated that pancreatic cancer cells with high Met expression exhibit cancer stem cell-like properties (34). Moreover, the pancreatic tumor cells with high Met expression showed higher tumorigenicity compared with cells with low Met expression or Met negative cells, and XL-184 treatment significantly inhibited in vivo tumor growth (34). Although the xenograft model from this study could not evaluate the effect of HGF produced outside of tumor cells, it has been reported that mouse HGF cannot activate the HGF receptor in cancer cells, and XL-184 treatment significantly inhibited in vivo tumor growth (34).

Recently, it has been reported that EGF signaling contributes to Met expression in lung cancer cell lines (36). This work demonstrates that EGF-Mediated signaling pathways can...
regulate Met at multiple levels, including mRNA expression and protein stability. Considering that K-Ras is a downstream effector of EGFR, it is probable that Met is regulated at both the level of mRNA and protein stability in K-Ras–driven cancer cells. Although we did not examine the effect of K-Ras ablation or MEK inhibitor treatment on Met protein stability, it is likely that EGFR activating mutation, EGF stimulation, and Ras activation all promote Met protein expression through similar mechanisms. In line with this, the transfection of N-Ras into Rasless MEFs also induced high Met expression (data not shown).

![Image]

**Figure 6.**
Met translation is enhanced in anchorage-independent culture conditions. A, representative polysome profiles showing relative levels of 40S ribosomal subunit (40S), 60S ribosomal subunit (60S), monosomes (80S), low molecular weight polysomes, and high molecular weight polysomes in monolayer and anchorage-independent culture conditions for Capan1 cells. B, qPCR analysis of Met mRNA levels in polysomal fractions for Capan1 cells under monolayer and anchorage-independent culture conditions. C, Capan1 cells were seeded on normal cell culture plates (monolayer) or ultra-low attachment plates (anchorage independent) in medium containing the indicated concentration of 4EGI-1 for 2 days. Cell lysates were immunoblotted with the indicated antibodies.

![Image]

**Figure 7.**
K-Ras–mediated regulation of Met expression and cell proliferation. K-Ras/MEK signaling pathway positively regulates Met mRNA levels. Met mRNA is translated by the elf-4F complex (elf-4E and elf-4G) via cap-dependent translation (left). In anchorage-independent culture conditions, enhanced Met translation increases Met expression. Increased Met expression results in increased cell proliferation (middle). In anchorage-independent culture conditions under K-Ras ablation, Met protein expression is decreased due to Met mRNA downregulation even with enhanced Met translation. Downregulation of Met signaling results in the suppression of cell proliferation.
Although both Met mRNA expression and protein stability are regulated similarly in monolayer and anchorage-independent culture conditions, cells cultured in anchorage-independent conditions contain higher Met protein (Figs. 2 and Fig. 3 and Supplementary Fig. S6). Our data indicate that this can be at least partially attributed to differences in Met mRNA translation, which we found to be increased in anchorage-independent conditions. Interestingly, Met translation was enhanced under anchorage-independent culture conditions despite a marked decrease in global mRNA translation. These results, along with the finding that Met expression is less sensitive to eIF4E inhibition under anchorage-independent conditions, suggest that Met mRNA may be translated, at least in part, through cap-independent mechanisms. It is possible that under anchorage-independent growth conditions, there is a mechanism for selective ribosome recruitment to Met mRNA, perhaps through an internal ribosome entry site (IRES). Although the mechanism remains unclear, it is tempting to speculate that increased expression of eIF4G3 could be involved, as eIF4G family members have been shown to promote IRES-dependent translation of certain mRNA transcripts (37–41).

Importantly, K-Ras regulates Met expression through MEK signaling in both monolayer and anchorage-independent culture conditions; however, in anchorage-independent conditions, Met expression is elevated by enhanced translation, leading to increased Met-driven cell proliferation. Thus, in anchorage-independent culture conditions, the depletion of K-Ras leads to down regulation of Met mRNA and subsequent growth suppression (Fig. 7).

The discovery of drugs that are effective against K-Ras mutant cancers is critical. Current initiatives to develop therapeutic agents to directly inhibit Ras are ongoing, and initiatives to inhibit pathways downstream of K-Ras, such as PI3K and MEK inhibitor combinations, are promising. Clinical trials for Met inhibitors are ongoing in a wide range of cancers, although previous clinical trials for Met inhibitors only targeted patients with noted Met amplifications. Our results suggest that Met inhibitors may be especially effective against K-Ras mutant cancers.

Disclosure of Potential Conflicts of Interest
S. Fujita-Sato is a researcher at Daiichi-Sankyo. D. Ruggero is a consultant/advisory board member for eFFECTOR Therapeutics. F. McCormick is a consultant/advisory board member for Daiichi Sankyo. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: S. Fujita-Sato, M. Truitt, D. Ruggero
Acquisition of data (provided animals, acquired and managed data, provided facilities, etc.): S. Fujita-Sato, J. Galeas, M. Truitt, C. Pitt, A. Urisman, D. Ruggero
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Fujita-Sato, J. Galeas, M. Truitt, A. Urisman, S. Bandypadhyay, D. Ruggero
Writing, review, and/or revision of the manuscript: S. Fujita-Sato, M. Truitt, C. Pitt, A. Urisman, D. Ruggero
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Pitt
Study supervision: F. McCormick

Grant Support
This work was supported by Daiichi-Sankyo and partially supported by NIH RO1 CA184624 (D. Ruggero).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 2, 2014; revised April 13, 2015; accepted May 1, 2015; published OnlineFirst May 14, 2015.

References
Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions

Saori Fujita-Sato, Jacqueline Galeas, Morgan Truitt, et al.

Cancer Res  Published OnlineFirst May 14, 2015.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-1623

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2015/05/21/0008-5472.CAN-14-1623.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.